Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies
Open Access
- 27 August 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in The AAPS Journal
- Vol. 23 (5), 1-13
- https://doi.org/10.1208/s12248-021-00623-8
Abstract
Avadomide is a cereblon E3 ligase modulator and a potent antitumor and immunomodulatory agent. Avadomide trials are challenged by neutropenia as a major adverse event and a dose-limiting toxicity. Intermittent dosing schedules supported by preclinical data provide a strategy to reduce frequency and severity of neutropenia; however, the identification of optimal dosing schedules remains a clinical challenge. Quantitative systems pharmacology (QSP) modeling offers opportunities for virtual screening of efficacy and toxicity levels produced by alternative dose and schedule regimens, thereby supporting decision-making in translational drug development. We formulated a QSP model to capture the mechanism of avadomide-induced neutropenia, which involves cereblon-mediated degradation of transcription factor Ikaros, resulting in a maturation block of the neutrophil lineage. The neutropenia model was integrated with avadomide-specific pharmacokinetic and pharmacodynamic models to capture dose-dependent effects. Additionally, we generated a disease-specific virtual patient population to represent the variability in patient characteristics and response to treatment observed for a diffuse large B-cell lymphoma trial cohort. Model utility was demonstrated by simulating the avadomide effect in the virtual population for various dosing schedules and determining the incidence of high-grade neutropenia, its duration, and the probability of recovery to low-grade neutropenia.Keywords
This publication has 50 references indexed in Scilit:
- What Can We Learn from Global Sensitivity Analysis of Biochemical Systems?PLOS ONE, 2013
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomideLeukemia, 2012
- Structural Identifiability of Systems Biology Models: A Critical Comparison of MethodsPLOS ONE, 2011
- GenSSI: a software toolbox for structural identifiability analysis of biological modelsBioinformatics, 2011
- Peculiarities of cell death mechanisms in neutrophilsCell Death & Differentiation, 2011
- Ikaros in B cell development and functionWorld Journal of Biological Chemistry, 2011
- In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 daysBlood, 2010
- An iterative identification procedure for dynamic modeling of biochemical networksBMC Systems Biology, 2010
- Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cellsJCI Insight, 2008
- Role of Mechanistically-Based Pharmacokinetic/Pharmacodynamic Models in Drug DevelopmentClinical Pharmacokinetics, 2006